Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rubitecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 18/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | GLA | P06280 | 3/20 | 0.78 |
| ▸ | RECQL | P46063 | 2/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | RAB9A | P51151 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rubitecan SCHEMBL8640 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL29379605 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL6426025 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL15539941 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL1652417 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL28223445 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL27953003 | 0.98 | ABCC4 (0.95) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL28308474 | 0.96 | ABCC4 (0.93) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL27598505 | 0.94 | ABCC3 (0.89) | ABCC4HTTABCC3ACHEPTGS1 | |
| SCHEMBL25932527 | 0.92 | ABCC4 (0.85) | ABCC4HTTABCC3ACHEPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 731 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098621-A1 | ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF | 百力司康生物医药(杭州)有限公司 | 2026-05-15 | — | — | WO | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| WO-2025227060-A1 | HETEROCYCLIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) IN COMBINATION WITH ADDITIONAL AGENTS FOR USE IN THE TREATMENT OF CANCER | INSILICO MEDICINE IP LIMITED (CN) | 2025-10-30 | — | — | WO | claimed |
| WO-2025101933-A1 | METHODS AND DEVICES FOR THE TREATMENT OF RESPIRATORY DISEASE | PNEUMA RESPIRATORY, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| WO-2025080590-A1 | CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2025-04-17 | — | — | WO | claimed |
| CN-119584992-A | Antibody-drug conjugates comprising antibodies against human TROP2 and uses thereof | 瑞嘉化学生物科学股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-119367549-A | Hydrophilic linkers and conjugates thereof | 芬兰吉利科斯有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-118557747-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-118105513-A | Conjugates comprising self-degrading groups and methods related thereto | 乐高化学生物科学股份有限公司 | 2024-05-31 | — | — | CN | claimed |
| WO-2024027708-A1 | MSLN ANTIBODY-DRUG CONJUGATE | 诺纳生物（苏州）有限公司 | 2024-02-08 | — | — | WO | claimed |
| CN-117279663-A | Antibody drug conjugate comprising antibody against human CLDN18.2 and use thereof | 乐高化学生物科学股份有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-117244076-A | Conjugates comprising self-degrading groups and methods related thereto | 乐高化学生物科学股份有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-116847875-A | Active cancer immunotherapy by immunomodulation via GLOBO series antigens | 台湾浩鼎生技股份有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-116806157-A | Linker-payload and conjugates thereof | 芬兰吉利科斯有限公司 | 2023-09-26 | — | — | CN | claimed |
| WO-2022256371-A1 | METHODS FOR PREDICTING AND TREATING CHEMORESISTANCE IN SMALL CELL LUNG CANCER PATIENTS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-12-08 | — | — | WO | claimed |
| CN-122080899-A | High-salt-and-high-temperature-resistant self-adaptive crosslinking acidolysis blocking remover and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12630603-B2 | Chimeric antigen receptor T cell therapy | KITE PHARMA, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2022036159-A2 | IMMUNOSTIMULATORY BACTERIA-BASED VACCINES, THERAPEUTICS, AND RNA DELIVERY PLATFORMS | Actym Therapeutics, Inc. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022036041-A1 | IMPROVING IMMUNE CELL FUNCTION | KITE PHARMA, INC (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20220047677-A1 | IMMUNE CELL FUNCTION | KITE PHARMA, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630603-B2 | Chimeric antigen receptor T cell therapy | CD4, ICOS, CD69 | TOP1 659/4885ABCC4 1767/4885HTT 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.